episode 901: COVID-19 clinical update #115 with Dr. Daniel Griffin
In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Limited cross-variant immunity without vaccination (Nature)
- EUA for boosters in 5-11 year olds (FDA)
- Stages of COVID-19 (AIDS Rev)
- B.1.1.529 attack rate in Australia (JID)
- Scent dogs (BMJ)
- Does Omicron affect pets? (CVMBS News)
- Paxlovid eligibility checklist (FDA)
- Supratherapeutic tacrolimus with nirmatrelvir/ritonavir (Op For Inf Dis)
- Is longer Paxlovid needed? (Reuters)
- How about Veklury? (Gilead)
- Fluvoxamine declined (FDA)
- Antigen positivity after isolation (MMWR)
- Inflammasome activation drives COVID-19 pathology (TWiV 900, Nature)
- PASC and viral antigen persistence in gut (Gastroenterol)
- GI symptoms and fecal shedding (Med)
- Contribute to ASTMH fundraiser at PW
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 901
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv